- Details
- In this conversation, Alicia Morgans and Neeraj Agarwal discuss the TALAPRO-2 trial, a phase three study investigating the effectiveness of combining ADT plus enzalutamide plus talazoparib in treating first line metastatic castrate-resistant prostate cancer. Agarwal presents the study's quality of life data at ASCO 2023, revealing the experimental arm significantly delayed the deterioration of pat...
|
- Details
- Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study's secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival benefit...
|
- Details
- In a discussion between Alicia Morgans and Alberto Bossi, they delved into the PEACE-1 data. Professor Bossi outlined the European study initiated by himself and Karim Fizazi, focusing on the potential impact of radiotherapy and abiraterone on the prognosis of metastatic prostate cancer patients. Discussing the study's results, Professor Bossi revealed no overall survival benefit from radiotherapy...
|
- Details
- Alicia Morgans host Fatima Karzai and Rana McKay to explore the National Cancer Institute Natural History Study. This study focuses on prostate cancer patients with unusual mutations and exceptional responses to treatments, aiming to understand their disease progression over time. The trial, conducted across multiple sites including UCSD, follows participants longitudinally, particularly those wit...
|
- Details
- Neal Shore discusses the EMBARK trial with Alicia Morgans. The study investigated whether enzalutamide plus leuprolide treatment or enzalutamide monotherapy could prolong metastasis-free survival compared with placebo plus leuprolide for men with high-risk biochemical relapse. The study's primary endpoint was met, with patients in the combination arm showing a 58% reduction in the risk of metastas...
|
- Details
- Pedro Barata speaks with Alicia Morgans about his presentations focusing on genetic and germline testing in patients with advanced prostate cancer. Dr. Barata highlights a study that found more than two-thirds of the patient population had not been tested for homologous recombination repair (HRR) mutations, and another analysis of over 8,100 patients with metastatic castration-resistant prostate c...
|
- Details
- Alicia Morgans hosts a discussion with Rahul Aggarwal about his ongoing research on DLL3 targeting BiTE therapy. DLL3 is expressed in an aggressive form of prostate cancer known as neuroendocrine prostate cancer. Dr. Aggarwal's study focuses on using an immunotherapeutic approach to target DLL3, using a compound developed by Amgen that enhances immune response. With 40 patients already enrolled in...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
- Details
- In this collaborative discussion, Alicia Morgans and Edward (Ted) Schaeffer examine the evolving guidelines for integrating PET imaging into the diagnosis and treatment of prostate cancer. Dr. Schaeffer emphasizes that these NCCN guidelines, which frequently adapt to new medical developments, act as a flexible framework rather than a rigid rulebook. The conversation explores the application of PSM...
|
- Details
- Alicia Morgans and Carsten-Henning Ohlmann discuss the SPARE trial, an exploratory phase two study involving chemo-naive metastatic castration-resistant prostate cancer patients. The trial compares the standard of care - ADT (Androgen Deprivation Therapy) plus abiraterone plus prednisone, versus abiraterone plus prednisone without the continuation of ADT. Preliminary results show no significant di...
|
